This research investigates how cells repair dangerous DNA double-strand breaks through the non-homologous end joining pathway. By identifying key proteins involved in this error-prone repair process, the work reveals new opportunities to sensitise cancer cells to radiation and chemotherapy, potentially improving treatment outcomes for aggressive cancers.

This research links two major treatment challenges in childhood acute lymphoblastic leukemia through ferroptosis, a lipid oxidation process regulated by selenium. By targeting selenium uptake in the brain and after chemotherapy, the work identifies potential new therapeutic strategies to reduce cancer cell survival and improve long-term treatment outcomes.

This research investigates a novel two-drug therapy for ovarian cancer that kills cancer cells without harming healthy tissues and partially reactivates the suppressed immune system. The PhD work explores how this immune “reawakening” occurs, aiming to identify new strategies to enhance it and create more effective, resistance-proof treatments.